Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Adagio Therapeutics, Inc. ADGI
$4.64
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
505676480.00000000
-
week52high
-
week52low
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-2.63300000
-
Last Dividend
0.00000000
-
Next Earnings Date
19 сент 2022 г. в 04:00
Описание компании
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Underweight | Underweight | 17 мая 2022 г. |
| Morgan Stanley | Underweight | Equal-Weight | 06 янв 2022 г. |
| Jefferies | Hold | Buy | 22 дек 2021 г. |
| Stifel | Hold | Buy | 15 дек 2021 г. |
| Morgan Stanley | Equal-Weight | Overweight | 15 дек 2021 г. |
| Morgan Stanley | Underweight | 14 сент 2022 г. | |
| Morgan Stanley | Underweight | Underweight | 16 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Hering David | A | 8000 | 8000 | 01 сент 2022 г. |
| Elia Marc | A | 9248250 | 584451 | 19 авг 2022 г. |
| Elia Marc | A | 8663799 | 1265549 | 18 авг 2022 г. |
| Elia Marc | A | 7398250 | 1000000 | 17 авг 2022 г. |
| Hering David | A | 2000000 | 2000000 | 05 июл 2022 г. |
| MEANWELL CLIVE | A | 150000 | 150000 | 22 июн 2022 г. |
| Berry Tamsin | A | 150000 | 150000 | 22 июн 2022 г. |
| Elia Marc | A | 150000 | 150000 | 22 июн 2022 г. |
| Mayer Howard | A | 75000 | 75000 | 22 июн 2022 г. |
| WYZGA MICHAEL S | A | 75000 | 75000 | 22 июн 2022 г. |
Новостная лента
Adagio Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire
06 сент 2022 г. в 16:01
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases, today announced participation in the following upcoming investor conferences:
Hedge Fund M28 Capital Increases Adagio Therapeutics (ADGI) Stake to 8.5%
24/7 Wall Street
22 авг 2022 г. в 20:08
Last Friday, health care focused hedge fund M28 Capital filed a 13D/A with the US Securities & Exchange Committee revealing it bought 2.85 million Adagio Therapeutics (US:ADGI) at an average of $4.28 per share, bringing its holding to 9.2 million, or 8.5% of the company.